T Cell
Top in hem/onc: T-cell therapy, multiple myeloma treatment
The FDA has cleared an investigational new drug application for T-cell therapy to treat high-risk patients with COVID-19. It was the top story in hematology/oncology last week.
FDA clears IND application for T-cell therapy to treat high-risk patients with COVID-19
The FDA cleared an investigational new drug application for ALVR109 for the treatment of high-risk adults with COVID-19 infection, according to the agent’s manufacturer.
T-cell therapy trial fails to meet primary efficacy endpoint for refractory NSCLC
A gamma-delta T-cell therapy failed to significantly prolong PFS for patients with treatment-refractory non-small cell lung cancer, according to study results presented at American Association for Cancer Research Virtual Annual Meeting II.
Commercial Off-the-Shelf CAR-T Still Years Away from the Clinic
Management of Pre-CAR-T Infusion Bridging Therapies
In this installment of In Practice, Leo I. Gordon, MD, FACP, co-director of the hematologic malignancies program at Northwestern University Feinberg School of Medicine and medical director of the John and Lillian Matthews Center for Cellular Therapy at Robert H. Lurie Comprehensive Cancer Center, discusses the challenges and best practices from the time the decision is made to seek chimeric antigen receptor T-cell therapy until the genetically engineered T cells are infused back into the patient.
Novel bispecific immune cell engager safe, clinically beneficial in HER2-positive tumors
T-cell Responses to Concurrent HIV and Herpesvirus Infections
An observational, prospective cohort study to discover new information about how HIV and herpes viruses interact with the immune system, with a goal of learning more about how T cells in the immune system respond to and fight off long-term (chronic) viruses, in order to improve medical care in the future.